Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
| GPCR Stock | 22.20 1.66 6.96% |
Slightly above 61% of Structure Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Structure Therapeutics American suggests that many traders are alarmed. Structure Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Structure Therapeutics American. Many technical investors use Structure Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Structure | Build AI portfolio with Structure Stock |
SAN FRANCISCO, June 03, 2024 -- Structure Therapeutics Inc. , a clinical-stage global biopharmaceutical company developing...
Read at globenewswire.com
 |
Structure Therapeutics Fundamental Analysis
We analyze Structure Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Structure Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Structure Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Structure Therapeutics is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Structure Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Structure Therapeutics stock to make a market-neutral strategy. Peer analysis of Structure Therapeutics could also be used in its relative valuation, which is a method of valuing Structure Therapeutics by comparing valuation metrics with similar companies.
Peers
Structure Therapeutics Related Equities
| XFOR | X4 Pharmaceuticals | 8.31 | ||||
| BMEA | Biomea Fusion | 7.19 | ||||
| IRON | Disc Medicine | 3.88 | ||||
| ABOS | Acumen Pharmaceuticals | 2.94 | ||||
| AMLX | Amylyx Pharmaceuticals | 2.30 | ||||
| HOOK | Hookipa Pharma | 1.90 | ||||
| TERN | Terns Pharmaceuticals | 1.66 | ||||
| MREO | Mereo BioPharma | 0.91 | ||||
| DAWN | Day One | 0.16 | ||||
| INZY | Inozyme Pharma | 0.25 | ||||
| ELDN | Eledon Pharmaceuticals | 1.90 |
Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.